Do we need biomarkers to predict the benefit of adding adjuvant taxanes for treatment of breast cancer?Jose Perez-Garcia
Breast Cancer Unit, Vall d Hebron University Hospital, Universitat Autonoma de Barcelona, Passeig Vall d Hebron 119 129, 08035 Barcelona, Spain
Breast Cancer Res 14:104. 2012
..For this reason, the Ki67 index might help to better define the group of patients who could have the optimal benefit...
Docetaxel combined with targeted therapies in metastatic breast cancerJavier Cortes
Department of Oncology, Vall d Hebron University Hospital, Passeig Vall d Hebron 119 129, 08035 Barcelona, Spain
Cancer Treat Rev 38:387-96. 2012
..Overall, docetaxel in combination with novel targeted agents in MBC appears to be highly active in patients with MBC, and such combinations represent promising treatment regimens for clinical investigation...
- Beyond taxanes: the next generation of microtubule-targeting agents
Javier Cortes
Breast Cancer Program, Department of Oncology, Vall d Hebron University Hospital, Vall d Hebron 119 129, Barcelona, Spain
Breast Cancer Res Treat 133:821-30. 2012
..The development of new microtubule-targeting agents helps to address the need for additional effective regimens for patients progressing after standard treatment with anthracycline- and taxane-containing regimens...
- Adverse events risk associated with bevacizumab addition to breast cancer chemotherapy: a meta-analysis
J Cortes
Department of Medical Oncology, Vall d Hebron University Hospital, Barcelona, Spain
Ann Oncol 23:1130-7. 2012
..A systematic review and meta-analysis was conducted to determine the risk of the most clinically relevant adverse outcomes associated with the use of bevacizumab in the treatment of breast cancer...
- Eribulin mesylate, a novel microtubule inhibitor in the treatment of breast cancer
Javier Cortes
Department of Oncology, Vall d Hebron University Hospital, Barcelona, Spain
Cancer Treat Rev 38:143-51. 2012
....
- Pregnancy after treatment of breast cancer in young women does not adversely affect the prognosis
Octavi Córdoba
Breast Cancer Unit, Service of Gynecology, Hospital Vall d Hebron, Barcelona, Spain
Breast 21:272-5. 2012
..009). Breast cancer patients presented a high number of unwanted pregnancies. Pregnancy after breast cancer not only did not adversely affect prognosis of the neoplasm but also may have a protective effect...
- Outcome of patients following hepatic resection for metastatic cutaneous and ocular melanoma
Mireia Caralt
Department of Hepatobiliopancreatic Surgery and Transplants, Hospital Universitari Vall d Hebron, Universitat Autonoma de Barcelona, Centro de Investigacion Biomedica en Red de Enfermedades Hepaticas y Digestivas CIBERehd, Passeig Vall d Hebron 119 129, 08035 Barcelona, Spain
J Hepatobiliary Pancreat Sci 18:268-75. 2011
..The aim of this study was to analyze the outcome of patients undergoing hepatic resection for melanoma liver metastases...
- Safety of bevacizumab in metastatic breast cancer patients undergoing surgery
Javier Cortes
Department of Oncology, Vall d Hebron University Hospital, Universitat Autonoma de Barcelona, Barcelona, Spain
Eur J Cancer 48:475-81. 2012
..Evaluate the safety of surgery in relation to bevacizumab in the first-line treatment of metastatic breast cancer (mBC) in two international trials...
- Phase II study of the halichondrin B analog eribulin mesylate in patients with locally advanced or metastatic breast cancer previously treated with an anthracycline, a taxane, and capecitabine
Javier Cortes
Vall d Hebron University Hospital, Barcelona, Spain
J Clin Oncol 28:3922-8. 2010
....
- Eribulin monotherapy versus treatment of physician's choice in patients with metastatic breast cancer (EMBRACE): a phase 3 open-label randomised study
Javier Cortes
Vall d Hebron University Hospital, Vall d Hebron Institute of Oncology, Barcelona, Spain
Lancet 377:914-23. 2011
..Eribulin mesilate is a non-taxane microtubule dynamics inhibitor with a novel mode of action. We aimed to compare overall survival of heavily pretreated patients receiving eribulin versus currently available treatments...
Prognostic factors for disease-free survival in patients with T3-4 or N+ rectal cancer treated with preoperative chemoradiation therapy, surgery, and intraoperative irradiationJuan A Diaz-Gonzalez
Department of Oncology, Clinica Universitaria, University of Navarra, Navarra, Spain
Int J Radiat Oncol Biol Phys 64:1122-8. 2006
..Potential predictive factors for response and disease-free survival, with intense local multidisciplinary approach, are analyzed...
- Complete pathological remission in a patient with hormone-receptor positive and c-erbB-2 expression-negative breast cancer treated with FAC chemotherapy during pregnancy
Octavi Córdoba
Breast Unit, Service of Obstetrics and Gynecology, Hospital Vail d Hebron, Autonomous University of Barcelona, Barcelona, Spain
Tumori 96:629-32. 2010
..This case illustrates how the integrated work of different specialists can obtain excellent oncological and obstetrical results in the care of pregnant women with breast cancer...
- Eribulin mesylate: a promising new antineoplastic agent for locally advanced or metastatic breast cancer
Javier Cortes
Department of Medical Oncology, Breast Cancer Unit, Vall d Hebron University Hospital, 08035 Barcelona, Spain
Future Oncol 7:355-64. 2011
..In addition, eribulin has a manageable tolerability profile, requires no premedication and has shorter infusion times than most other microtubule-targeted agents...
- Cost-effectiveness analyses of docetaxel versus paclitaxel once weekly in patients with metastatic breast cancer in progression following anthracycline chemotherapy, in Spain
Carmen Frias
Corporacio Sanitaria Parc Tauli, Barcelona, Spain
Clin Transl Oncol 12:692-700. 2010
..Our aim was to evaluate the cost-effectiveness of docetaxel versus weekly paclitaxel regimen in patients with metastatic breast cancer previously treated with anthracycline from the Spanish National Health Service (NHS) perspective...
- Phase II trial of pertuzumab and trastuzumab in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer that progressed during prior trastuzumab therapy
Jose Baselga
Vall d Hebron Institute of Oncology, Vall d Hebron University Hospital, Paseo Vall d Hebron 119 129, Barcelona, Spain E 08035
J Clin Oncol 28:1138-44. 2010
..This phase II trial assessed the efficacy and safety profile of the combination in patients with HER2-positive breast cancer whose disease had progressed during prior trastuzumab-based therapy...
- Advances in first-line treatment for patients with HER-2+ metastatic breast cancer
Leticia De Mattos-Arruda
Medical Oncology Department, Vall d Hebron University Hospital, Barcelona, Spain
Oncologist 17:631-44. 2012
..Although anti-HER-2 therapy with trastuzumab and chemotherapy is the standard first-line treatment, the best therapeutic regimen has yet to be defined, and new strategies are evolving...
- Implication of breast cancer phenotype for patients with leptomeningeal carcinomatosis
Davis Torrejón
Breast Cancer Center, Vall d Hebron University Hospital, Passeig de la Vall d Hebron 119 129, 08035 Barcelona, Spain
Breast 22:19-23. 2013
..We aimed to study the implications of breast cancer (BC) subtypes for the development and prognosis of leptomeningeal carcinomatosis (LC)...
- Breast cancer and HSP90 inhibitors: is there a role beyond the HER2-positive subtype?
Leticia De Mattos-Arruda
Medical Oncology Department, Vall d Hebron University Hospital, Paseo Vall d Hebron 119 129, 08035 Barcelona, Spain
Breast 21:604-7. 2012
..In this article, we revisit HSP90 inhibitors in the context of breast cancer and discuss some notable preclinical data that reveal potential roles in both hormonal receptor-positive and triple negative breast tumor subtypes...
- Nonpegylated liposomal doxorubicin (TLC-D99), paclitaxel, and trastuzumab in HER-2-overexpressing breast cancer: a multicenter phase I/II study
Javier Cortes
Vall d Hebron University Hospital, Barcelona, Spain
Clin Cancer Res 15:307-14. 2009
....
- HER2 and hormone receptor-positive breast cancer--blocking the right target
Javier Cortes
Vall d Hebron University Hospital, Oncology Department, Breast Cancer Unit, Paseo Vall d Hebron 119 129, 08035 Barcelona, Spain
Nat Rev Clin Oncol 8:307-11. 2011
..In this article, we highlight the importance of considering chemotherapy and anti-HER2 therapy as the standard of care in HER2-positive and hormone receptor-positive tumors...
- Targeting the microtubules in breast cancer beyond taxanes: the epothilones
Javier Cortes
Department of Oncology, Vall d Hebron University Hospital, Barcelona, Spain
Oncologist 12:271-80. 2007
..The results of these studies are eagerly awaited and it is anticipated that epothilones may become an important treatment option in patients with breast cancer...
- Eribulin mesylate as a microtubule inhibitor for treatment of patients with metastatic breast cancer
Eva Muñoz-Couselo
Breast Cancer Unit, Vall d Hebron Institute of Oncology, Vall d Hebron University Hospital, Universitat Autonoma de Barcelona, Barcelona, Spain
Onco Targets Ther 4:185-92. 2011
..This review will focus on eribulin as a new active agent for MBC and its role in the management of breast disease...
- Prognostic and predictive factors and genetic analysis of early breast cancer
Miguel Martin
Department of Medical Oncology, Hospital General Universitario Gregorio Maranon, Madrid, Spain
Clin Transl Oncol 11:634-42. 2009
....
- Current situation: lower genital tract pathology and colposcopy training in spanish gynecology and obstetrics residents
Núria Laia Rodríguez-Mias
Department of Obstetrics and Gynecology, Hospital Sant Joan de Deu, Universitat de Barcelona, Barcelona, Spain
J Low Genit Tract Dis 17:12-6. 2013
..This didactic change was carried out under the auspices of the Asociación Española de Patología Cervical y Colposcopia and the Sociedad Española Ginecología y Obstetricia and its Resident Section...
- Chemotherapy and role of the proliferation marker Ki-67 in digestive neuroendocrine tumors
Eduardo Vilar
Department of Medical Oncology, Vall d Hebron University Hospital, Barcelona 08035, Spain
Endocr Relat Cancer 14:221-32. 2007
..Also a comprehensive review of the literature about chemotherapy in NETs is presented...
- Molecular pathways: targeting hsp90--who benefits and who does not
Maurizio Scaltriti
Massachusetts General Hospital Cancer Center, Massachusetts General Hospital, Harvard Medical School, Boston, MA 02129, USA
Clin Cancer Res 18:4508-13. 2012
..Several ongoing studies testing different combinations of Hsp90 inhibitors with other targeted agents will confirm whether Hsp90 inhibition can potentiate the efficacy of targeted therapy and/or prevent the emergence of drug resistance...
- Hepatic resection for liver metastases as part of the "oncosurgical" treatment of metastatic breast cancer
Mireia Caralt
Department of Hepatobiliopancreatic Surgery and Transplants, Hospital Universitari Vall d Hebron, Paseo Vall d Hebron119 129, Barcelona, 08035, Spain
Ann Surg Oncol 15:2804-10. 2008
..Metastatic breast cancer is considered an incurable disease despite new therapies. Recent studies suggest that liver resection associated with systemic treatment may improve patient survival...
- Cyclin E amplification/overexpression is a mechanism of trastuzumab resistance in HER2+ breast cancer patients
Maurizio Scaltriti
Departments of Medical Oncology and Molecular Pathology, Vall d Hebron Institute of Oncology, 08035 Barcelona, Spain
Proc Natl Acad Sci U S A 108:3761-6. 2011
....
